首页 > 最新文献

Bjog-An International Journal of Obstetrics and Gynaecology最新文献

英文 中文
Care of late intrauterine fetal death and stillbirth 晚期宫内胎儿死亡和死胎的护理:绿顶指南第 55 号。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-28 DOI: 10.1111/1471-0528.17844
Christy Burden, Abi Merriel, Danya Bakhbakhi, Alexander Heazell, Dimitrios Siassakos, the Royal College of Obstetricians and Gynaecologists
<div> <section> <div> <ul> <li>A combination of mifepristone and a prostaglandin preparation should usually be recommended as the first-line intervention for induction of labour (Grade B).</li> <li> <p>A single 200 milligram dose of mifepristone is appropriate for this indication, followed by: </p><ul> <li>24<sup>+0</sup>–24<sup>+6</sup> weeks of gestation – 400 micrograms buccal/sublingual/vaginal/oral of misoprostol every 3 hours;</li> <li>25<sup>+0</sup>–27<sup>+6</sup> weeks of gestation – 200 micrograms buccal/sublingual/vaginal/oral of misoprostol every 4 hours;</li> <li>from 28<sup>+0</sup> weeks of gestation – 25–50 micrograms vaginal every 4 hours, or 50–100 micrograms oral every 2 hours [Grade C].</li> </ul> </li> <li>There is insufficient evidence available to recommend a specific regimen of misoprostol for use at more than 28<sup>+0</sup> weeks of gestation in women who have had a previous caesarean birth or transmural uterine scar [Grade D].</li> <li>Women with more than two lower segment caesarean births or atypical scars should be advised that the safety of induction of labour is unknown [Grade D].</li> <li>Staff should be educated in discussing mode of birth with bereaved parents. Vaginal birth is recommended for most women, but caesarean birth will need to be considered for some [Grade D].</li> <li>A detailed informed discussion should be undertaken with parents of both physical and psychological aspects of a vaginal birth versus a caesarean birth [Grade C].</li> <li>Parents should be cared for in an environment that provides adequate safety according to individual clinical circumstance, while meeting their needs to grieve and feel supported in doing so (GPP).</li> <li>Clinical and laboratory tests should be recommended to assess maternal wellbeing (including coagulopathy) and to determine the cause of fetal death, the chance of recurrence and possible means of avoiding future pregnancy complications [Grade D].</li> <l
通常应建议将米非司酮和前列腺素制剂联合使用,作为引产的一线干预措施(B 级)。米非司酮的单次剂量为 200 毫克,然后再使用:妊娠 24+0-24+6 周--400 微克米索前列醇口服/舌下/阴道/口服,每 3 小时一次;妊娠 25+0-27+6 周--200 微克米索前列醇口服/舌下/阴道/口服,每 4 小时一次;妊娠 28+0 周起--25-50 微克米索前列醇阴道/口服,每 4 小时一次,或 50-100 微克米索前列醇口服,每 2 小时一次 [C 级]。目前还没有足够的证据来推荐一种特定的米索前列醇治疗方案,适用于妊娠超过 28+0 周、曾进行过剖宫产或有横纹子宫疤痕的妇女[D 级]。应告知有两次以上下段剖宫产或不典型疤痕的妇女,引产的安全性尚不明确[D级]。应教育员工与失去亲人的父母讨论分娩方式。建议大多数产妇采用阴道分娩,但有些产妇需要考虑剖腹产[D级]。应与父母详细讨论阴道分娩与剖腹产的生理和心理问题[C级]。应根据个人临床情况,为父母提供足够安全的护理环境,同时满足他们哀悼的需求,并在哀悼过程中感受到支持(GPP)。建议进行临床和实验室检查,以评估产妇的健康状况(包括凝血功能障碍),并确定胎儿死亡的原因、复发的可能性以及避免未来妊娠并发症的可能方法[D级]。应告知父母,经过全面调查(包括尸体解剖和胎盘组织学),多达四分之三的晚期宫内胎儿死亡可以找到可能或可能的原因[B 级]。应向所有父母提供胎儿细胞遗传学检测,并在获得书面同意后进行(GPP)。应告知父母,尸检提供的信息有时对今后的妊娠管理至关重要[B 级]。
{"title":"Care of late intrauterine fetal death and stillbirth","authors":"Christy Burden,&nbsp;Abi Merriel,&nbsp;Danya Bakhbakhi,&nbsp;Alexander Heazell,&nbsp;Dimitrios Siassakos,&nbsp;the Royal College of Obstetricians and Gynaecologists","doi":"10.1111/1471-0528.17844","DOIUrl":"10.1111/1471-0528.17844","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;div&gt;\u0000 \u0000 &lt;ul&gt;\u0000 \u0000 \u0000 &lt;li&gt;A combination of mifepristone and a prostaglandin preparation should usually be recommended as the first-line intervention for induction of labour (Grade B).&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;\u0000 \u0000 &lt;p&gt;A single 200 milligram dose of mifepristone is appropriate for this indication, followed by: \u0000\u0000 &lt;/p&gt;&lt;ul&gt;\u0000 \u0000 &lt;li&gt;24&lt;sup&gt;+0&lt;/sup&gt;–24&lt;sup&gt;+6&lt;/sup&gt; weeks of gestation – 400 micrograms buccal/sublingual/vaginal/oral of misoprostol every 3 hours;&lt;/li&gt;\u0000 \u0000 &lt;li&gt;25&lt;sup&gt;+0&lt;/sup&gt;–27&lt;sup&gt;+6&lt;/sup&gt; weeks of gestation – 200 micrograms buccal/sublingual/vaginal/oral of misoprostol every 4 hours;&lt;/li&gt;\u0000 \u0000 &lt;li&gt;from 28&lt;sup&gt;+0&lt;/sup&gt; weeks of gestation – 25–50 micrograms vaginal every 4 hours, or 50–100 micrograms oral every 2 hours [Grade C].&lt;/li&gt;\u0000 &lt;/ul&gt;\u0000 \u0000 &lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;There is insufficient evidence available to recommend a specific regimen of misoprostol for use at more than 28&lt;sup&gt;+0&lt;/sup&gt; weeks of gestation in women who have had a previous caesarean birth or transmural uterine scar [Grade D].&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Women with more than two lower segment caesarean births or atypical scars should be advised that the safety of induction of labour is unknown [Grade D].&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Staff should be educated in discussing mode of birth with bereaved parents. Vaginal birth is recommended for most women, but caesarean birth will need to be considered for some [Grade D].&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;A detailed informed discussion should be undertaken with parents of both physical and psychological aspects of a vaginal birth versus a caesarean birth [Grade C].&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Parents should be cared for in an environment that provides adequate safety according to individual clinical circumstance, while meeting their needs to grieve and feel supported in doing so (GPP).&lt;/li&gt;\u0000 \u0000 \u0000 &lt;li&gt;Clinical and laboratory tests should be recommended to assess maternal wellbeing (including coagulopathy) and to determine the cause of fetal death, the chance of recurrence and possible means of avoiding future pregnancy complications [Grade D].&lt;/li&gt;\u0000 \u0000 \u0000 &lt;l","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 1","pages":"e1-e41"},"PeriodicalIF":4.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17844","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review 治疗女性慢性盆腔疼痛的生物心理社会疗法:系统综述》(Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review.
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-27 DOI: 10.1111/1471-0528.17987
Selina Johnson, Alison Bradshaw, Rebecca Bresnahan, Emma Evans, Katie Herron, Dharani K. Hapangama

Background/Objective

Current guidelines recommend biopsychosocial-informed treatment for chronic pelvic pain (CPP). The objective of this systematic review was to describe the available biopsychosocial approaches for the treatment of CPP, and the outcomes reported, to understand how guideline-recommended treatments can be applied.

Search Strategy

MEDLINE, CINAHL, PsycINFO, EMBASE, Emcare, AMED and Cochrane trial registries were searched (inception to 17 November 2023).

Selection Criteria

CPP Studies in women where the principal treatment modality was a biopsychosocial approach were included. Prospero registration: CRD42022374256.

Data Collection/Analysis

Data extraction included study setting, population, study design, intervention characteristics and outcome measures and is described via a narrative synthesis.

Results

The review included 14 RCTs (871 patients) and identified four broad intervention categories (Acceptance Commitment Therapy n = 2, Cognitive Behavioural Therapy n = 6, Mindfulness-based approaches n = 2, and Physiotherapy-based interventions n = 4). Pain science education (PSE) and, exposure/engagement with valued activity were recognised as important aspects of treatment regardless of intervention type. The most utilised outcomes were pain reduction and emotional functioning, with all studies reporting improvements in these domains. Heterogeneity in outcomes prevented efficacy comparison. High risk of bias was identified in six studies (1/4 physiotherapy-based approaches, 2/6 CBT, 1/2 ACT and 2/2 mindfulness-based interventions).

Conclusions

CBT and ACT-based biopsychosocial approaches were found effective in reducing pain and improving psychometric outcomes for CPP. Evaluation indicated PSE, and exposure/engagement in valued activity are important components of biopsychosocial management. Outcome heterogeneity needs to be addressed in future trials.

背景/目的:目前的指南推荐对慢性盆腔痛(CPP)进行生物心理社会学治疗。本系统性综述的目的是描述治疗 CPP 的现有生物心理社会方法以及所报告的结果,以了解如何应用指南推荐的治疗方法:检索了 MEDLINE、CINAHL、PsycINFO、EMBASE、Emcare、AMED 和 Cochrane 试验登记处(开始至 2023 年 11 月 17 日):纳入以生物心理社会疗法为主要治疗方法的女性 CPP 研究。Prospero 注册:数据收集/分析:数据提取包括研究环境、研究人群、研究设计、干预特点和结果测量,并通过叙述性综合进行描述:综述包括 14 项 RCT(871 名患者),确定了四大干预类别(接纳承诺疗法 n = 2、认知行为疗法 n = 6、正念方法 n = 2 和物理治疗干预 n = 4)。无论干预类型如何,疼痛科学教育(PSE)和接触/参与有价值的活动都被认为是治疗的重要方面。最常用的结果是疼痛减轻和情绪功能,所有研究都报告了这些方面的改善。由于结果的异质性,无法进行疗效比较。6项研究(1/4项基于物理治疗的方法、2/6项CBT、1/2项ACT和2/2项基于正念的干预)存在高偏倚风险:结论:以 CBT 和 ACT 为基础的生物心理社会方法可有效减轻 CPP 患者的疼痛并改善其心理测量结果。评估表明,PSE 和暴露/参与有价值的活动是生物心理社会管理的重要组成部分。在未来的试验中需要解决结果异质性的问题。
{"title":"Biopsychosocial Approaches for the Management of Female Chronic Pelvic Pain: A Systematic Review","authors":"Selina Johnson,&nbsp;Alison Bradshaw,&nbsp;Rebecca Bresnahan,&nbsp;Emma Evans,&nbsp;Katie Herron,&nbsp;Dharani K. Hapangama","doi":"10.1111/1471-0528.17987","DOIUrl":"10.1111/1471-0528.17987","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background/Objective</h3>\u0000 \u0000 <p>Current guidelines recommend biopsychosocial-informed treatment for chronic pelvic pain (CPP). The objective of this systematic review was to describe the available biopsychosocial approaches for the treatment of CPP, and the outcomes reported, to understand how guideline-recommended treatments can be applied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Search Strategy</h3>\u0000 \u0000 <p>MEDLINE, CINAHL, PsycINFO, EMBASE, Emcare, AMED and Cochrane trial registries were searched (inception to 17 November 2023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Selection Criteria</h3>\u0000 \u0000 <p>CPP Studies in women where the principal treatment modality was a biopsychosocial approach were included. Prospero registration: CRD42022374256.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data Collection/Analysis</h3>\u0000 \u0000 <p>Data extraction included study setting, population, study design, intervention characteristics and outcome measures and is described via a narrative synthesis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The review included 14 RCTs (871 patients) and identified four broad intervention categories (Acceptance Commitment Therapy <i>n</i> = 2, Cognitive Behavioural Therapy <i>n</i> = 6, Mindfulness-based approaches <i>n</i> = 2, and Physiotherapy-based interventions <i>n</i> = 4). Pain science education (PSE) and, exposure/engagement with valued activity were recognised as important aspects of treatment regardless of intervention type. The most utilised outcomes were pain reduction and emotional functioning, with all studies reporting improvements in these domains. Heterogeneity in outcomes prevented efficacy comparison. High risk of bias was identified in six studies (1/4 physiotherapy-based approaches, 2/6 CBT, 1/2 ACT and 2/2 mindfulness-based interventions).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CBT and ACT-based biopsychosocial approaches were found effective in reducing pain and improving psychometric outcomes for CPP. Evaluation indicated PSE, and exposure/engagement in valued activity are important components of biopsychosocial management. Outcome heterogeneity needs to be addressed in future trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"266-277"},"PeriodicalIF":4.7,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142512369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-Trimester Prediction Models Based on Maternal Characteristics for Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis 基于孕产妇特征的不良妊娠结局首胎预测模型:系统回顾和元分析
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-24 DOI: 10.1111/1471-0528.17983
Jacintha C. A. van Eekhout, Ellis C. Becking, Peter G. Scheffer, Ioannis Koutsoliakos, Caroline J. Bax, Lidewij Henneman, Mireille N. Bekker, Ewoud Schuit

Background

Early risk stratification can facilitate timely interventions for adverse pregnancy outcomes, including preeclampsia (PE), small-for-gestational-age neonates (SGA), spontaneous preterm birth (sPTB) and gestational diabetes mellitus (GDM).

Objectives

To perform a systematic review and meta-analysis of first-trimester prediction models for adverse pregnancy outcomes.

Search Strategy

The PubMed database was searched until 6 June 2024.

Selection Criteria

First-trimester prediction models based on maternal characteristics were included. Articles reporting on prediction models that comprised biochemical or ultrasound markers were excluded.

Data Collection and Analysis

Two authors identified articles, extracted data and assessed risk of bias and applicability using PROBAST.

Main results

A total of 77 articles were included, comprising 30 developed models for PE, 15 for SGA, 11 for sPTB and 35 for GDM. Discriminatory performance in terms of median area under the curve (AUC) of these models was 0.75 [IQR 0.69–0.78] for PE models, 0.62 [0.60–0.71] for SGA models of nulliparous women, 0.74 [0.72–0.74] for SGA models of multiparous women, 0.65 [0.61–0.67] for sPTB models of nulliparous women, 0.71 [0.68–0.74] for sPTB models of multiparous women and 0.71 [0.67–0.76] for GDM models. Internal validation was performed in 40/91 (43.9%) of the models. Model calibration was reported in 21/91 (23.1%) models. External validation was performed a total of 96 times in 45/91 (49.5%) of the models. High risk of bias was observed in 94.5% of the developed models and in 58.3% of the external validations.

Conclusions

Multiple first-trimester prediction models are available, but almost all suffer from high risk of bias, and internal and external validations were often not performed. Hence, methodological quality improvement and assessment of the clinical utility are needed.

早期风险分层有助于及时干预不良妊娠结局,包括子痫前期(PE)、小于妊娠年龄新生儿(SGA)、自发性早产(sPTB)和妊娠糖尿病(GDM)。
{"title":"First-Trimester Prediction Models Based on Maternal Characteristics for Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis","authors":"Jacintha C. A. van Eekhout,&nbsp;Ellis C. Becking,&nbsp;Peter G. Scheffer,&nbsp;Ioannis Koutsoliakos,&nbsp;Caroline J. Bax,&nbsp;Lidewij Henneman,&nbsp;Mireille N. Bekker,&nbsp;Ewoud Schuit","doi":"10.1111/1471-0528.17983","DOIUrl":"10.1111/1471-0528.17983","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Early risk stratification can facilitate timely interventions for adverse pregnancy outcomes, including preeclampsia (PE), small-for-gestational-age neonates (SGA), spontaneous preterm birth (sPTB) and gestational diabetes mellitus (GDM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To perform a systematic review and meta-analysis of first-trimester prediction models for adverse pregnancy outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Search Strategy</h3>\u0000 \u0000 <p>The PubMed database was searched until 6 June 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Selection Criteria</h3>\u0000 \u0000 <p>First-trimester prediction models based on maternal characteristics were included. Articles reporting on prediction models that comprised biochemical or ultrasound markers were excluded.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data Collection and Analysis</h3>\u0000 \u0000 <p>Two authors identified articles, extracted data and assessed risk of bias and applicability using PROBAST.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main results</h3>\u0000 \u0000 <p>A total of 77 articles were included, comprising 30 developed models for PE, 15 for SGA, 11 for sPTB and 35 for GDM. Discriminatory performance in terms of median area under the curve (AUC) of these models was 0.75 [IQR 0.69–0.78] for PE models, 0.62 [0.60–0.71] for SGA models of nulliparous women, 0.74 [0.72–0.74] for SGA models of multiparous women, 0.65 [0.61–0.67] for sPTB models of nulliparous women, 0.71 [0.68–0.74] for sPTB models of multiparous women and 0.71 [0.67–0.76] for GDM models. Internal validation was performed in 40/91 (43.9%) of the models. Model calibration was reported in 21/91 (23.1%) models. External validation was performed a total of 96 times in 45/91 (49.5%) of the models. High risk of bias was observed in 94.5% of the developed models and in 58.3% of the external validations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Multiple first-trimester prediction models are available, but almost all suffer from high risk of bias, and internal and external validations were often not performed. Hence, methodological quality improvement and assessment of the clinical utility are needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"243-265"},"PeriodicalIF":4.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17983","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142490046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pregnancy-Associated Maternal Mortality Within One Year After Childbirth: Population-Based Cohort Study 产后一年内与妊娠相关的孕产妇死亡率:基于人口的队列研究。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1471-0528.17985
Nadia Arshad, Rolv Skjærven, Kari Klungsøyr, Linn Marie Sørbye, Liv Grimstvedt Kvalvik, Nils-Halvdan Morken
<div> <section> <h3> Objective</h3> <p>The objective of this study is to assess associations between pregnancy complications and pregnancy-associated maternal mortality (PAM) within 1 year after childbirth.</p> </section> <section> <h3> Design</h3> <p>Population-based cohort study.</p> </section> <section> <h3> Setting</h3> <p>Norway, 1967–2020.</p> </section> <section> <h3> Population</h3> <p>1 237 254 mothers with one or more singleton pregnancies registered in the Medical Birth Registry, 1967–2019 and followed in the Cause of Death Registry to 2020.</p> </section> <section> <h3> Method<b>s</b></h3> <p>Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for maternal education, age, year of first childbirth and chronic medical conditions.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>PAM by lifetime history of pregnancy complications: placental abruption, preeclampsia, preterm birth, perinatal death, small for gestational age (< 2.5 percentile), gestational diabetes and gestational hypertension.</p> </section> <section> <h3> Results</h3> <p>Crude OR for PAM was 4.24 (95% CI 3.53–5.10), if complications occurred in the last pregnancy, whereas 2.52 (2.08–3.06) if complications occurred in the first pregnancy, compared to mothers without complications in any pregnancy. Adjusted ORs for PAM when complications occurred in the last pregnancy were, for placental abruption 3.75 (1.20–11.72), preeclampsia: 4.42 (3.17–6.15), preterm birth: 4.32 (3.25–5.75), perinatal death: 24.18 (16.66–35.08), small for gestational age: 2.90 (1.85–4.54), gestational diabetes: 1.43 (0.63–3.25) and pregnancy hypertension: 2.05 (1.12–3.74) compared to mothers without complications. The OR for PAM increased slightly by increasing the number of complicated pregnancies but the trend was stronger for increasing number of complications in the last pregnancy (e.g., during 1999–2019: one complication; 4.14 [2.79–6.13], two complications; 11.50 [6.81–19.43]).</p> </section> <section> <h3> Conclusion</h3> <p>Complications in the last pregnancy were more strongly associated with PAM than those in the first pregnancy
目的本研究旨在评估妊娠并发症与产后1年内妊娠相关孕产妇死亡率(PAM)之间的关系。方法采用逻辑回归法计算几率比(ORs)和 95% 置信区间(CIs),并根据产妇教育程度、年龄、初产妇年份和慢性病情况进行调整。主要结果测量PAM与终生妊娠并发症史的关系:胎盘早剥、子痫前期、早产、围产期死亡、胎龄小(< 2.5 百分位数)、妊娠糖尿病和妊娠高血压。结果与任何一次妊娠均无并发症的母亲相比,如果最后一次妊娠出现并发症,则PAM的粗略OR为4.24(95% CI为3.53-5.10);如果第一次妊娠出现并发症,则PAM的粗略OR为2.52(2.08-3.06)。当并发症发生在最后一次妊娠时,PAM 的调整 OR 为:胎盘早剥 3.75(1.20-11.72)、子痫前期:4.42(3.17-6.15)、早产:4.32(3.25-5.75)、围产期死亡:24.18(16.66-35.08)、胎龄小:2.90(1.85-4.54)、妊娠糖尿病:1.43(0.63-3.25)和妊娠高血压:2.05(1.12-3.74)。随着并发症妊娠次数的增加,PAM的OR值略有增加,但最后一次妊娠并发症次数增加的趋势更强(例如,1999-2019年期间:一次并发症;4.14 [2.79-6.13],两次并发症;11.50 [6.81-19.43])。
{"title":"Pregnancy-Associated Maternal Mortality Within One Year After Childbirth: Population-Based Cohort Study","authors":"Nadia Arshad,&nbsp;Rolv Skjærven,&nbsp;Kari Klungsøyr,&nbsp;Linn Marie Sørbye,&nbsp;Liv Grimstvedt Kvalvik,&nbsp;Nils-Halvdan Morken","doi":"10.1111/1471-0528.17985","DOIUrl":"10.1111/1471-0528.17985","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The objective of this study is to assess associations between pregnancy complications and pregnancy-associated maternal mortality (PAM) within 1 year after childbirth.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Population-based cohort study.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Norway, 1967–2020.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Population&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;1 237 254 mothers with one or more singleton pregnancies registered in the Medical Birth Registry, 1967–2019 and followed in the Cause of Death Registry to 2020.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Method&lt;b&gt;s&lt;/b&gt;&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Logistic regression was used to calculate odds ratios (ORs) with 95% confidence intervals (CIs), adjusted for maternal education, age, year of first childbirth and chronic medical conditions.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;PAM by lifetime history of pregnancy complications: placental abruption, preeclampsia, preterm birth, perinatal death, small for gestational age (&lt; 2.5 percentile), gestational diabetes and gestational hypertension.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Crude OR for PAM was 4.24 (95% CI 3.53–5.10), if complications occurred in the last pregnancy, whereas 2.52 (2.08–3.06) if complications occurred in the first pregnancy, compared to mothers without complications in any pregnancy. Adjusted ORs for PAM when complications occurred in the last pregnancy were, for placental abruption 3.75 (1.20–11.72), preeclampsia: 4.42 (3.17–6.15), preterm birth: 4.32 (3.25–5.75), perinatal death: 24.18 (16.66–35.08), small for gestational age: 2.90 (1.85–4.54), gestational diabetes: 1.43 (0.63–3.25) and pregnancy hypertension: 2.05 (1.12–3.74) compared to mothers without complications. The OR for PAM increased slightly by increasing the number of complicated pregnancies but the trend was stronger for increasing number of complications in the last pregnancy (e.g., during 1999–2019: one complication; 4.14 [2.79–6.13], two complications; 11.50 [6.81–19.43]).&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Complications in the last pregnancy were more strongly associated with PAM than those in the first pregnancy","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"365-374"},"PeriodicalIF":4.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17985","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non-Inferiority Trial 米索前列醇口服溶液或口服片剂用于引产(MISOBEST):随机对照非劣效性试验。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-23 DOI: 10.1111/1471-0528.17986
Elin Svensk, Emelie Bessfelt, Sophia Brismar Wendel, Helena Kopp Kallner, Tove Wallström
<div> <section> <h3> Objective</h3> <p>To assess if off-label oral solution of misoprostol compared with licensed oral tablet of misoprostol approved for induction of labour (IOL) is as efficient in resulting in vaginal delivery within 24 h, using a non-inferiority design.</p> </section> <section> <h3> Design</h3> <p>Prospective, randomised, non-inferiority, open-label, blinded endpoint trial.</p> </section> <section> <h3> Setting</h3> <p>Two tertiary level hospitals, Stockholm, Sweden, January 2022 to May 2023.</p> </section> <section> <h3> Population</h3> <p>In all, 874 women, without previous caesarean section, with an unripe cervix and a singleton, cephalic foetus at 37 + 0 to 42 + 0 gestational weeks, with a normal cardiotocography, planned for IOL were included.</p> </section> <section> <h3> Methods</h3> <p>Women were randomised 1:1 to intervention (25 μg oral solution of misoprostol) or control (25 μg oral tablet of misoprostol) two-hourly for a maximum of eight doses. Subsequent methods of induction followed clinical practice.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>The primary outcome was vaginal delivery within 24 h tested using non-inferiority testing procedures at a non-inferiority margin of 5 percentage points. Secondary efficacy outcomes were tested for superiority of either treatment. Analyses were by intention-to-treat.</p> </section> <section> <h3> Results</h3> <p>There were 207 (47.4%) vaginal deliveries within 24 h for women receiving oral solution and 192 (43.9%) vaginal deliveries within 24 h for women receiving oral tablet, establishing non-inferiority with an absolute risk difference of 3.4% (95% CI −3.2% to 10.0%). Women receiving oral solution required fewer doses to reach active labour than women receiving oral tablet (5.7 vs. 6.1, <i>p</i> = 0.007). There were no significant differences for other secondary or safety outcomes.</p> </section> <section> <h3> Conclusions</h3> <p>Off-label oral solution of misoprostol was non-inferior to the licensed oral tablet regarding efficacy of IOL defined as vaginal delivery within 24 h.</p> </section> <section>
设计前瞻性、随机、非劣效、开放标签、盲法终点试验。设置2022年1月至2023年5月,瑞典斯德哥尔摩两家三级医院。方法将874名妇女按1:1随机分配到干预组(25微克米索前列醇口服溶液)或对照组(25微克米索前列醇口服片剂),每两小时一次,最多8次。主要结局指标:主要结局为24小时内阴道分娩,采用非劣效性测试程序进行测试,非劣效性差值为5个百分点。次要疗效结果检测两种治疗方法的优劣。结果接受口服溶液治疗的妇女有207人(47.4%)在24小时内经阴道分娩,而接受口服片剂治疗的妇女有192人(43.9%)在24小时内经阴道分娩。与接受口服片剂治疗的妇女相比,接受口服溶液治疗的妇女达到活跃产程所需的剂量更少(5.7 对 6.1,P = 0.007)。结论在24小时内阴道分娩的IOL疗效方面,米索前列醇标签外口服溶液不劣于已获许可的口服片剂:NCT05424445。
{"title":"Misoprostol as Oral Solution or Oral Tablet for Induction of Labour (MISOBEST): A Randomised Controlled Non-Inferiority Trial","authors":"Elin Svensk,&nbsp;Emelie Bessfelt,&nbsp;Sophia Brismar Wendel,&nbsp;Helena Kopp Kallner,&nbsp;Tove Wallström","doi":"10.1111/1471-0528.17986","DOIUrl":"10.1111/1471-0528.17986","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To assess if off-label oral solution of misoprostol compared with licensed oral tablet of misoprostol approved for induction of labour (IOL) is as efficient in resulting in vaginal delivery within 24 h, using a non-inferiority design.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Prospective, randomised, non-inferiority, open-label, blinded endpoint trial.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Two tertiary level hospitals, Stockholm, Sweden, January 2022 to May 2023.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Population&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In all, 874 women, without previous caesarean section, with an unripe cervix and a singleton, cephalic foetus at 37 + 0 to 42 + 0 gestational weeks, with a normal cardiotocography, planned for IOL were included.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Women were randomised 1:1 to intervention (25 μg oral solution of misoprostol) or control (25 μg oral tablet of misoprostol) two-hourly for a maximum of eight doses. Subsequent methods of induction followed clinical practice.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The primary outcome was vaginal delivery within 24 h tested using non-inferiority testing procedures at a non-inferiority margin of 5 percentage points. Secondary efficacy outcomes were tested for superiority of either treatment. Analyses were by intention-to-treat.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;There were 207 (47.4%) vaginal deliveries within 24 h for women receiving oral solution and 192 (43.9%) vaginal deliveries within 24 h for women receiving oral tablet, establishing non-inferiority with an absolute risk difference of 3.4% (95% CI −3.2% to 10.0%). Women receiving oral solution required fewer doses to reach active labour than women receiving oral tablet (5.7 vs. 6.1, &lt;i&gt;p&lt;/i&gt; = 0.007). There were no significant differences for other secondary or safety outcomes.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Off-label oral solution of misoprostol was non-inferior to the licensed oral tablet regarding efficacy of IOL defined as vaginal delivery within 24 h.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 ","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"288-296"},"PeriodicalIF":4.7,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17986","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142488187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study 子宫内膜异位症患者的口腔、阴道和粪便微生物特征作为潜在的非侵入性诊断生物标志物:前瞻性队列研究
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-21 DOI: 10.1111/1471-0528.17979
Chloe Hicks, Mathew Leonardi, Xin-Yi Chua, Lisa Mari-Breedt, Mercedes Espada, Emad M. El-Omar, George Condous, Fatima El-Assaad
<div> <section> <h3> Objective</h3> <p>To identify a microbial signature for endometriosis for use as a diagnostic non-invasive biomarker.</p> </section> <section> <h3> Design</h3> <p>Prospective cohort pilot study.</p> </section> <section> <h3> Setting</h3> <p>Nepean Hospital and UNSW Microbiome Research Centre, Australia.</p> </section> <section> <h3> Population</h3> <p>Sixty-four age- and sex-matched subjects (<i>n</i> = 19 healthy control (HC); <i>n =</i> 24 non-endometriosis (N-ENDO) and <i>n =</i> 21 confirmed endometriosis (ENDO)). All study participants, besides healthy controls, underwent laparoscopic surgical assessment for endometriosis, and histology was performed on excised lesions.</p> </section> <section> <h3> Methods</h3> <p>Oral, stool and, vaginal samples were self-collected at a single time point for healthy controls, and preoperatively for patients undergoing laparoscopy. Samples underwent 16S rRNA amplicon sequencing, followed by bioinformatics analysis.</p> </section> <section> <h3> Main Outcome Measures</h3> <p>Compositional differences between cohorts as identified by diversity analyses, and differentially abundant microbial taxa, as identified by LEfSE analysis.</p> </section> <section> <h3> Results</h3> <p>The composition of the oral (adjusted <i>p</i> = 0.003), and stool (adjusted <i>p</i> = 0.042) microbiota is different between the three cohorts. Differentially abundant taxa are present within each cohort as identified by LEfSE analysis. Particularly<i>, Fusobacterium</i> was enriched in the oral samples of patients with moderate/severe endometriosis.</p> </section> <section> <h3> Conclusions</h3> <p>Taxonomic and compositional differences were found between the microbiota in the mouth, gut and, vagina of patients with and without endometriosis and healthy controls. <i>Fusobacterium</i> was enriched in patients with moderate/severe endometriosis. <i>Fusobacterium</i> is noted as a key pathogen in periodontal disease, a common comorbidity in endometriosis. These findings suggest a role for the oral, stool and, vaginal microbiome in endometriosis, and present potential for microbial-based treatments and the design of a di
确定子宫内膜异位症的微生物特征,作为诊断性非侵入性生物标志物。
{"title":"Oral, Vaginal, and Stool Microbial Signatures in Patients With Endometriosis as Potential Diagnostic Non-Invasive Biomarkers: A Prospective Cohort Study","authors":"Chloe Hicks,&nbsp;Mathew Leonardi,&nbsp;Xin-Yi Chua,&nbsp;Lisa Mari-Breedt,&nbsp;Mercedes Espada,&nbsp;Emad M. El-Omar,&nbsp;George Condous,&nbsp;Fatima El-Assaad","doi":"10.1111/1471-0528.17979","DOIUrl":"10.1111/1471-0528.17979","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;To identify a microbial signature for endometriosis for use as a diagnostic non-invasive biomarker.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Design&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Prospective cohort pilot study.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Setting&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Nepean Hospital and UNSW Microbiome Research Centre, Australia.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Population&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Sixty-four age- and sex-matched subjects (&lt;i&gt;n&lt;/i&gt; = 19 healthy control (HC); &lt;i&gt;n =&lt;/i&gt; 24 non-endometriosis (N-ENDO) and &lt;i&gt;n =&lt;/i&gt; 21 confirmed endometriosis (ENDO)). All study participants, besides healthy controls, underwent laparoscopic surgical assessment for endometriosis, and histology was performed on excised lesions.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Oral, stool and, vaginal samples were self-collected at a single time point for healthy controls, and preoperatively for patients undergoing laparoscopy. Samples underwent 16S rRNA amplicon sequencing, followed by bioinformatics analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Main Outcome Measures&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Compositional differences between cohorts as identified by diversity analyses, and differentially abundant microbial taxa, as identified by LEfSE analysis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The composition of the oral (adjusted &lt;i&gt;p&lt;/i&gt; = 0.003), and stool (adjusted &lt;i&gt;p&lt;/i&gt; = 0.042) microbiota is different between the three cohorts. Differentially abundant taxa are present within each cohort as identified by LEfSE analysis. Particularly&lt;i&gt;, Fusobacterium&lt;/i&gt; was enriched in the oral samples of patients with moderate/severe endometriosis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Taxonomic and compositional differences were found between the microbiota in the mouth, gut and, vagina of patients with and without endometriosis and healthy controls. &lt;i&gt;Fusobacterium&lt;/i&gt; was enriched in patients with moderate/severe endometriosis. &lt;i&gt;Fusobacterium&lt;/i&gt; is noted as a key pathogen in periodontal disease, a common comorbidity in endometriosis. These findings suggest a role for the oral, stool and, vaginal microbiome in endometriosis, and present potential for microbial-based treatments and the design of a di","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"326-336"},"PeriodicalIF":4.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17979","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment 先天性巨细胞病毒感染:筛查、诊断和治疗的最新进展:第 56 号科学影响文件。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-21 DOI: 10.1111/1471-0528.17966
A. Khalil, P. T. Heath, C. E. Jones, A. Soe, Y. G. Ville, the Royal College of Obstetricians and Gynaecologists
<div> <p>Cytomegalovirus (CMV) is the most common cause of viral infection in newborn babies, and affects 1 in 200 of all live born infants in high-income countries; and 1 in 71 in low- and middle-income countries. It is a major cause of hearing loss and brain damage.</p> <p>Women may get CMV infection for the first time during pregnancy (primary infection) or may experience ‘non-primary’ infection, either by reactivation of previous CMV infection or by a new infection with a different strain of the virus. The most common source of infection to pregnant women is the saliva and urine of young children. Therefore, all pregnant women, especially those in regular contact with young children, should be informed about hygiene-based measures to reduce the risks, e.g. handwashing.</p> <p>The UK National Screening Committee recommends against universal antenatal or newborn screening for CMV. Testing for CMV is usually offered only to women who develop symptoms of influenza, glandular fever or hepatitis (liver inflammation) during pregnancy, or for those whom a routine ultrasound scan detects fetal anomalies that suggests possible CMV infection.</p> <p>The risk of harm to the fetus is greatest following primary CMV infection of the woman in early pregnancy, and appears to be very low following infection after 12 weeks of pregnancy. Babies with CMV infection at birth may have jaundice, a rash, enlarged liver or spleen, a small brain, or be small for their gestational age. Around 1 in 8 babies born with CMV infection will have clinically detectable signs at birth. The rest will not have any features detectable by clinical examination alone. Therefore, all infants with CMV infection at birth should be followed up at a minimum of up to 2 years of age or later, depending upon the disease status, to check hearing and brain development.</p> <p>Following primary CMV infection in the first 12 weeks of pregnancy, if the woman starts taking the antiviral medicine valaciclovir (valacyclovir) it reduces the risk of the baby becoming infected.</p> <p>Where CMV infection of the fetus in the womb has been confirmed (by amniocentesis, for example), regular ultrasound scans should be offered every 2–3 weeks until birth. Detailed assessment of the fetal brain is an essential part of these scans. Where maternal CMV infection occurs, but fetal infection is not confirmed, repeated ultrasound scans of the fetus should be offered every 2–3 weeks until birth.</p> <p>In infected fetuses, as well as ultrasound scans, an MRI scan of the brain should be offered at 28–32 weeks of gestation (and sometimes repeated 3–4 weeks later) to assess for any signs of harm to the fetal brain.</p> <p>All babies born to women with confirmed or suspected CMV infection should be tested for CMV with a urine or saliva sample within the first 21 days of life.</p> <p>In newborns with symptomatic CMV infection at bir
巨细胞病毒(CMV)是导致新生儿病毒感染的最常见原因,在高收入国家,每 200 个活产婴儿中就有 1 人感染;在中低收入国家,每 71 个活产婴儿中就有 1 人感染。它是造成听力损失和脑损伤的主要原因。妇女可能在怀孕期间首次感染 CMV(原发性感染),也可能经历 "非原发性 "感染,可能是以前的 CMV 感染再次活化,也可能是新感染了不同的病毒株。孕妇最常见的感染源是幼儿的唾液和尿液。因此,所有孕妇,尤其是经常与幼儿接触的孕妇,都应了解减少风险的卫生措施,如洗手。英国国家筛查委员会建议不要进行普遍的产前或新生儿 CMV 筛查。通常只有在怀孕期间出现流感、传染性单核细胞增多症或肝炎(肝脏炎症)症状的妇女,或在常规超声波扫描中发现胎儿异常并提示可能感染 CMV 的妇女,才会进行 CMV 检测。妇女在孕早期初次感染 CMV 后,胎儿受到伤害的风险最大,而在怀孕 12 周后感染 CMV,胎儿受到伤害的风险似乎很低。出生时感染 CMV 的婴儿可能会有黄疸、皮疹、肝脏或脾脏肿大、小脑或胎龄小。大约每 8 个感染 CMV 的婴儿中就有 1 个会在出生时出现可被临床检测到的体征。其余的婴儿则无法仅通过临床检查发现任何特征。因此,所有出生时感染 CMV 的婴儿都应根据病情至少在 2 岁或 2 岁以后接受随访,以检查听力和大脑发育情况。在怀孕前 12 周感染原发性 CMV 后,如果孕妇开始服用抗病毒药物伐昔洛韦(valacyclovir),就会降低婴儿受感染的风险。如果子宫内的胎儿已确诊感染了 CMV(例如通过羊膜穿刺术),则应每 2-3 周定期进行超声波扫描,直至胎儿出生。对胎儿大脑的详细评估是这些扫描的重要组成部分。如果母体感染了 CMV,但胎儿未确诊感染,则应每 2-3 周对胎儿进行一次重复的超声波扫描,直至出生。对于受感染的胎儿,除了超声波扫描外,还应在妊娠 28-32 周时进行脑部核磁共振成像扫描(有时 3-4 周后会重复扫描),以评估胎儿脑部是否有受到伤害的迹象。所有确诊或疑似感染 CMV 的妇女所生的婴儿都应在出生后 21 天内接受尿液或唾液样本的 CMV 检测。对于出生时患有无症状 CMV 感染的新生儿,使用抗病毒药物(缬更昔洛韦或更昔洛韦)治疗可减少六分之五婴儿的听力损失,并改善部分婴儿的长期脑发育结果。目前还没有获得许可的 CMV 疫苗。
{"title":"Congenital Cytomegalovirus Infection: Update on Screening, Diagnosis and Treatment","authors":"A. Khalil,&nbsp;P. T. Heath,&nbsp;C. E. Jones,&nbsp;A. Soe,&nbsp;Y. G. Ville,&nbsp;the Royal College of Obstetricians and Gynaecologists","doi":"10.1111/1471-0528.17966","DOIUrl":"10.1111/1471-0528.17966","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;p&gt;Cytomegalovirus (CMV) is the most common cause of viral infection in newborn babies, and affects 1 in 200 of all live born infants in high-income countries; and 1 in 71 in low- and middle-income countries. It is a major cause of hearing loss and brain damage.&lt;/p&gt;\u0000 &lt;p&gt;Women may get CMV infection for the first time during pregnancy (primary infection) or may experience ‘non-primary’ infection, either by reactivation of previous CMV infection or by a new infection with a different strain of the virus. The most common source of infection to pregnant women is the saliva and urine of young children. Therefore, all pregnant women, especially those in regular contact with young children, should be informed about hygiene-based measures to reduce the risks, e.g. handwashing.&lt;/p&gt;\u0000 &lt;p&gt;The UK National Screening Committee recommends against universal antenatal or newborn screening for CMV. Testing for CMV is usually offered only to women who develop symptoms of influenza, glandular fever or hepatitis (liver inflammation) during pregnancy, or for those whom a routine ultrasound scan detects fetal anomalies that suggests possible CMV infection.&lt;/p&gt;\u0000 &lt;p&gt;The risk of harm to the fetus is greatest following primary CMV infection of the woman in early pregnancy, and appears to be very low following infection after 12 weeks of pregnancy. Babies with CMV infection at birth may have jaundice, a rash, enlarged liver or spleen, a small brain, or be small for their gestational age. Around 1 in 8 babies born with CMV infection will have clinically detectable signs at birth. The rest will not have any features detectable by clinical examination alone. Therefore, all infants with CMV infection at birth should be followed up at a minimum of up to 2 years of age or later, depending upon the disease status, to check hearing and brain development.&lt;/p&gt;\u0000 &lt;p&gt;Following primary CMV infection in the first 12 weeks of pregnancy, if the woman starts taking the antiviral medicine valaciclovir (valacyclovir) it reduces the risk of the baby becoming infected.&lt;/p&gt;\u0000 &lt;p&gt;Where CMV infection of the fetus in the womb has been confirmed (by amniocentesis, for example), regular ultrasound scans should be offered every 2–3 weeks until birth. Detailed assessment of the fetal brain is an essential part of these scans. Where maternal CMV infection occurs, but fetal infection is not confirmed, repeated ultrasound scans of the fetus should be offered every 2–3 weeks until birth.&lt;/p&gt;\u0000 &lt;p&gt;In infected fetuses, as well as ultrasound scans, an MRI scan of the brain should be offered at 28–32 weeks of gestation (and sometimes repeated 3–4 weeks later) to assess for any signs of harm to the fetal brain.&lt;/p&gt;\u0000 &lt;p&gt;All babies born to women with confirmed or suspected CMV infection should be tested for CMV with a urine or saliva sample within the first 21 days of life.&lt;/p&gt;\u0000 &lt;p&gt;In newborns with symptomatic CMV infection at bir","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 2","pages":"e42-e52"},"PeriodicalIF":4.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17966","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142479896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Birth Outcomes After Pertussis and Influenza Diagnosed in Pregnancy: A Retrospective, Population-Based Study 妊娠期诊断出百日咳和流感后的分娩结果:一项基于人群的回顾性研究。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-18 DOI: 10.1111/1471-0528.17984
Jane E. Frawley, Wen-Qiang He, Lisa McCallum, Peter McIntyre, Andrew Hayen, Heather Gidding, Elizabeth Sullivan, Bette Liu

Objective

Adverse birth outcomes and the maternal severity of influenza in pregnancy are well documented but information on pertussis is limited.

Design

Population-based linkage data were collected during 2001–2016.

Setting

New South Wales, Australia.

Population or Sample

A total of 1 453 037 singleton births.

Methods

Cox regression was used to estimate the associations between pertussis or influenza during pregnancy and birth outcomes with adjustment of covariates.

Main Outcome Measures

Adverse birth outcomes (preterm birth and low birth weight).

Results

Among 1 453 037 singleton births over 16 years, we identified pertussis in 925 (49; 5.3% hospitalised) and influenza in 2850 (1092; 38.3% hospitalised) women during pregnancy. Cases of pertussis were similarly distributed by trimester (32% 3rd) whereas 46% of influenza cases were in the 3rd trimester. Younger age, previous birth, and being overseas-born were associated with both pertussis and influenza, whereas identifying as Aboriginal or Torres Strait Islander, hypertension or diabetes before and during pregnancy, and a number of other factors were only associated with influenza. Both pertussis and influenza in pregnancy were associated with increased risk of preterm birth (pertussis: aHR = 1.30, 95% CI 1.01–1.68; influenza: aHR = 1.56, 95% CI 1.36–1.79) and these increased risks were greater when infections in the period within 2 weeks of birth were considered (pertussis: aHR = 2.36, 95% CI 1.26–4.41; influenza: aHR = 2.29, 95% CI 1.78–2.96).

Conclusions

Maternal pertussis and influenza infections close to the time of birth were associated with adverse birth outcomes. These findings highlight the benefits of vaccination during pregnancy.

目的不良出生结局和妊娠期流感的产妇严重程度已被充分记录,但有关百日咳的信息却很有限。设计2001-2016年间收集了基于人群的关联数据。主要结局指标不良出生结局(早产和低出生体重).结果在 16 年间出生的 1 453 037 例单胎婴儿中,我们在 925 名(49 例;5.3% 住院)孕期妇女中发现了百日咳病例,在 2850 名(1092 例;38.3% 住院)孕期妇女中发现了流感病例。百日咳病例按孕期分布相似(32%为第三孕期),而 46%的流感病例为第三孕期。年龄较小、生过孩子和在海外出生与百日咳和流感都有关,而土著居民或托雷斯海峡岛民身份、怀孕前和怀孕期间的高血压或糖尿病以及其他一些因素只与流感有关。妊娠期百日咳和流感都与早产风险增加有关(百日咳:aHR = 1.30,95% CI 1.01-1.68;流感:aHR = 1.56,95% CI 1.36-1.79),如果考虑到出生后两周内的感染情况,这些增加的风险更大(百日咳:aHR = 2.结论产妇在临近分娩时感染百日咳和流感与不良出生结局有关。这些发现凸显了孕期接种疫苗的益处。
{"title":"Birth Outcomes After Pertussis and Influenza Diagnosed in Pregnancy: A Retrospective, Population-Based Study","authors":"Jane E. Frawley,&nbsp;Wen-Qiang He,&nbsp;Lisa McCallum,&nbsp;Peter McIntyre,&nbsp;Andrew Hayen,&nbsp;Heather Gidding,&nbsp;Elizabeth Sullivan,&nbsp;Bette Liu","doi":"10.1111/1471-0528.17984","DOIUrl":"10.1111/1471-0528.17984","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Adverse birth outcomes and the maternal severity of influenza in pregnancy are well documented but information on pertussis is limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>Population-based linkage data were collected during 2001–2016.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Setting</h3>\u0000 \u0000 <p>New South Wales, Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Population or Sample</h3>\u0000 \u0000 <p>A total of 1 453 037 singleton births.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cox regression was used to estimate the associations between pertussis or influenza during pregnancy and birth outcomes with adjustment of covariates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main Outcome Measures</h3>\u0000 \u0000 <p>Adverse birth outcomes (preterm birth and low birth weight).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 1 453 037 singleton births over 16 years, we identified pertussis in 925 (49; 5.3% hospitalised) and influenza in 2850 (1092; 38.3% hospitalised) women during pregnancy. Cases of pertussis were similarly distributed by trimester (32% 3rd) whereas 46% of influenza cases were in the 3rd trimester. Younger age, previous birth, and being overseas-born were associated with both pertussis and influenza, whereas identifying as Aboriginal or Torres Strait Islander, hypertension or diabetes before and during pregnancy, and a number of other factors were only associated with influenza. Both pertussis and influenza in pregnancy were associated with increased risk of preterm birth (pertussis: aHR = 1.30, 95% CI 1.01–1.68; influenza: aHR = 1.56, 95% CI 1.36–1.79) and these increased risks were greater when infections in the period within 2 weeks of birth were considered (pertussis: aHR = 2.36, 95% CI 1.26–4.41; influenza: aHR = 2.29, 95% CI 1.78–2.96).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Maternal pertussis and influenza infections close to the time of birth were associated with adverse birth outcomes. These findings highlight the benefits of vaccination during pregnancy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"355-364"},"PeriodicalIF":4.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parents', Families', Communities' and Healthcare Professionals' Experiences of Care Following Neonatal Death in Healthcare Facilities in LMICs: A Systematic Review and Meta-Ethnography 低收入国家医疗机构新生儿死亡后父母、家庭、社区和医护人员的护理经验:系统回顾与元数据分析》。
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-18 DOI: 10.1111/1471-0528.17982
Charlotte Wilson, Bethany Atkins, Richard Molyneux, Claire Storey, Hannah Blencowe

Background

Ninety-eight percent of neonatal deaths worldwide occur in low- and middle-income countries (LMICs), yet there is little bereavement care guidance available for these settings.

Objectives

To explore parents', families' and healthcare professionals' experiences of care after neonatal death in healthcare facilities in LMICs.

Search Strategy and Selection Criteria

Four databases were searched for peer-reviewed literature, meeting the inclusion criteria of qualitative studies exploring the experiences of people who provided or received bereavement care following neonatal death in a LMIC healthcare setting.

Data Collection and Analysis

Data were collected by two independent reviewers, collated through line-by-line coding and then reciprocal and refutational translation, and analysed through Noblit and Hare's seven-step meta-ethnography approach to create first-, second- and third-order themes.

Main Results

Seven first-order themes extracted from the literature included emotional responses, social relationships, staff and systems, religion, connecting with the baby, coping strategies and economic concerns. From these data, three third-order themes arose: The individual, the healthcare setting and the community/context.

Conclusions

Overarching themes in bereavement care shape grief responses and are often similar across geographical locations. Analysing these similarities allows a deeper understanding of the important elements of bereavement care and may be helpful to inform the creation of high-quality, bereavement care guidelines suitable for use in LMIC settings.

背景全世界 98% 的新生儿死亡发生在低收入和中等收入国家 (LMIC),但几乎没有针对这些环境的丧亲护理指南。检索策略和筛选标准在四个数据库中检索了同行评审过的文献,这些文献均符合定性研究的纳入标准,这些定性研究探讨了在低收入国家医疗机构中新生儿死亡后提供或接受丧亲护理的人员的经历。数据收集与分析数据由两名独立审稿人收集,通过逐行编码进行整理,然后进行互译和反驳翻译,并通过 Noblit 和 Hare 的七步元民族志方法进行分析,以创建一阶、二阶和三阶主题。主要结果从文献中提取的七个一阶主题包括情绪反应、社会关系、员工和系统、宗教、与婴儿的联系、应对策略和经济问题。从这些数据中产生了三个三阶主题:结论丧亲护理的总体主题决定了悲伤的反应,而且在不同的地理位置往往具有相似性。对这些相似性进行分析可以加深对丧亲关怀重要因素的理解,并有助于制定适合低收入和中等收入国家环境的高质量丧亲关怀指南。
{"title":"Parents', Families', Communities' and Healthcare Professionals' Experiences of Care Following Neonatal Death in Healthcare Facilities in LMICs: A Systematic Review and Meta-Ethnography","authors":"Charlotte Wilson,&nbsp;Bethany Atkins,&nbsp;Richard Molyneux,&nbsp;Claire Storey,&nbsp;Hannah Blencowe","doi":"10.1111/1471-0528.17982","DOIUrl":"10.1111/1471-0528.17982","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ninety-eight percent of neonatal deaths worldwide occur in low- and middle-income countries (LMICs), yet there is little bereavement care guidance available for these settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To explore parents', families' and healthcare professionals' experiences of care after neonatal death in healthcare facilities in LMICs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Search Strategy and Selection Criteria</h3>\u0000 \u0000 <p>Four databases were searched for peer-reviewed literature, meeting the inclusion criteria of qualitative studies exploring the experiences of people who provided or received bereavement care following neonatal death in a LMIC healthcare setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Data Collection and Analysis</h3>\u0000 \u0000 <p>Data were collected by two independent reviewers, collated through line-by-line coding and then reciprocal and refutational translation, and analysed through Noblit and Hare's seven-step meta-ethnography approach to create first-, second- and third-order themes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Main Results</h3>\u0000 \u0000 <p>Seven first-order themes extracted from the literature included emotional responses, social relationships, staff and systems, religion, connecting with the baby, coping strategies and economic concerns. From these data, three third-order themes arose: The individual, the healthcare setting and the community/context.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overarching themes in bereavement care shape grief responses and are often similar across geographical locations. Analysing these similarities allows a deeper understanding of the important elements of bereavement care and may be helpful to inform the creation of high-quality, bereavement care guidelines suitable for use in LMIC settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"132 3","pages":"346-354"},"PeriodicalIF":4.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17982","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142449349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RCOG 2024 RCOG 2024
IF 4.7 1区 医学 Q1 OBSTETRICS & GYNECOLOGY Pub Date : 2024-10-15 DOI: 10.1111/1471-0528.17946

Abstract Withdrawn

Abstract Withdrawn

Abstract Withdrawn

撤回摘要 撤回摘要 撤回摘要 撤回摘要
{"title":"RCOG 2024","authors":"","doi":"10.1111/1471-0528.17946","DOIUrl":"10.1111/1471-0528.17946","url":null,"abstract":"<p>Abstract Withdrawn</p><p>Abstract Withdrawn</p><p>Abstract Withdrawn</p>","PeriodicalId":50729,"journal":{"name":"Bjog-An International Journal of Obstetrics and Gynaecology","volume":"131 S5","pages":"3-214"},"PeriodicalIF":4.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1471-0528.17946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bjog-An International Journal of Obstetrics and Gynaecology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1